Experience with vincristine - Associated neurotoxicity

East African Medical Journal

Volumn 78, Issue 7, 2001, Pages 376-378

  Othieno Abinya, N A ^a   Nyabola, L O ^a  

^a UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; NEOPLASM; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 0035411368     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: 10.4314/eamj.v78i7.     Document Type: Article

References (14)

1. Legha S.S. Vincristine neurotoxicity: Pathophysiology and management. Med. Toxicol. 1986; 1:421-427.
2. Tuxen M.K. and Hansen S.W. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 1994:20:191.
3. DeVita V.T. and Serpick A. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Proc. Amer. Ass. Cancer Res 1967; 8:13.
4. DeVita V.T., Serpick A.A. and Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern. Med 1970; 73: 891-894.
5. Lowernbraun S, DeVita V.T. and Serpick A.A. Combination chemotherapy with nitrogen mustard, vincrisitne, procarbazine and prednisone in previously treated patients with Hodgkin's disease. Blood. 1970; 36:704-717.
6. Moore M.E., Jones S. E. and Bull J. M. et. al. MOPP chemotherapy for advanced Hodgkin's disease: Prognostic factors in 81 patients. Cancer 1973; 32:52-60.
7. Bakemeier R.F., Anderson, J.R. and Castello W. et al. BCVPP chemotherapy for advanced E-Hodgkin's disease: Evidence for greater duration of complete remission, greater survival and less toxicity than with a MOPP regimen. Ann. Intern. Med. 1984; 101:447-456.
8. Navia B.A. and Price RW: Central and peripheral nervous system complications of AIDS. Clin. Immunol. Allergy. 1987; 6: 543.
9. Rowinsky, E.K. and Donehower, R.C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 1991; 14:115-119.
10. Carde, P., MacKintosh, R. and Rosenberg, S.A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP therapy. J Clin. Oncol. 1983; 1:146-153.
11. Haim, N. et al. Full dose vincristine(without a 2 mg dose limit) in the treatment of lymphomas. Cancer. 1994; 15:2515.
12. Monfardini, S., Tancini, G. and Delena, N. et al. Cyclophosphamide, vincristine and prednisone (CVP) versus adriamycin, bleomycin and prednisone (ABP) in stage IV Non-Hodgkin's Lymphomas. Med. Paediat. Oncol. 1977; 3:67.
13. Griffiths, J.D., Stark, R.J., Ding, J.C. and Cooper, I.A. Vincristine neurotoxicity in Charcot-Marie-Tooth syndrome. Med. J. Aust. 1985; 143:305.
14. McGuire, S.A., Gospe, S.M., Jr. and Dahl, G. Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I. Med. Paediat. Oncol. 1989; 17:520.